US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invesco Global Clean Energy ETF

13.69

+0.13000.96%

Volume:165.36K

Turnover:2.28M

Market Cap:79.06M

PE:- -

High:13.83

Open:13.66

Low:13.66

Close:13.56

Loading ...

Overview Company News Filings

Press Release: ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

Press Release: ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

Press Release: ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse

Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH

Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PBD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBD\",,,,,undefined,":{"symbol":"PBD","market":"US","secType":"STK","nameCN":"Invesco Global Clean Energy ETF","latestPrice":13.69,"timestamp":1753128000000,"preClose":13.56,"halted":0,"volume":165357,"delay":0,"floatShares":5775000,"shares":5775000,"eps":0,"marketStatus":"Pre-Mkt","change":0.13,"latestTime":"07-22 05:12:12 EDT","open":13.66,"high":13.83,"low":13.66,"amount":2280459.042296,"amplitude":0.012537,"askPrice":14.01,"askSize":49,"bidPrice":5.52,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1753191000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":13.69,"sharesOutstanding":5775000,"nav":13.44537,"aum":78637160.54,"dividendRate":0.025566,"bidAskSpread":0.002427,"postHourTrading":{"tag":"盘后","latestPrice":13.69,"preClose":13.69,"latestTime":"16:10 EDT","volume":10,"amount":136.77,"timestamp":1753128605412},"volumeRatio":8.551061100906725,"impliedVol":0.3677,"impliedVolPercentile":0.7871},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBD\",,,,,undefined,":{"symbol":"PBD","floatShares":5775000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":8.551061100906725,"shares":5775000,"dividePrice":0.35,"high":13.83,"amplitude":0.012537,"preClose":13.56,"low":13.66,"week52Low":9.02,"pbRate":"--","week52High":14.17,"institutionHeld":0,"latestPrice":13.69,"committee":0.342282,"eps":0,"divideRate":0.025566,"volume":165357,"delay":0,"ttmEps":0,"open":13.66,"prevYearClose":11.57,"prevWeekClose":13.56,"prevMonthClose":12.6011,"prevQuarterClose":12.6011,"fiveDayClose":13.2,"twentyDayClose":12.076,"sixtyDayClose":10.4833},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542513417","title":"Press Release: ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2542513417","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542513417?lang=en_us&edition=fundamental","pubTime":"2025-06-12 18:45","pubTimestamp":1749725100,"startTime":"0","endTime":"0","summary":"LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates , today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $100.0 million private investment in public equity  financing. In the PIPE, ADC Therapeutics is selling 13.0 million common shares at $3.53 per share and pre-funded warrants to purchase 15.7 million common shares at $3.43, per pre-funded warrant, which is the price per common share in the PIPE minus the exercise price of CHF 0.08 per pre-funded warrant.Gross proceeds from the PIPE financing are anticipated to be approximately $100.0 million before deducting placement agent fees and offering expenses. The PIPE is expected to close on June 16, 2025, subject to customary closing conditions. ADC Therapeutics intends to use the net proceeds from the PIPE to fund multiple catalysts pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4081","BK4022","BK4195","BK4505","ADCT","R","BK4007","BK4231","ADC","BK4139","BK4211","EMA","BK4232","BK4539","BK4080","PBD","PFS"],"gpt_icon":0},{"id":"2535025235","title":"Press Release: ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535025235","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535025235?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:00","pubTimestamp":1747224000,"startTime":"0","endTime":"0","summary":"LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress  and the 18 International Conference on Malignant Lymphoma ; ZYNLONTA plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability. Cash runway expected to fund multiple catalysts into the second half of 2026. LAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates , today reported financial results for the first quarter ended March 31, 2025, and provided recent operational updates.\"We are encouraged by the promising LOTIS-7 abstract data, which we believe demonstrate the potential for ZYNLONTA plus glofitamab to be a best-in-class combination in a dynamic market,\" said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. \"Coupled with the progress of our LOTIS-5 confirmatory trial, we are confident in our path forward and the potential of ZYNLON","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LENZ","BK4539","BK4161","CR","BK4080","ADCT","BK4195","ADC","PFS","R","BK4139","ORR","BK4007","BK4211","BK4232","BK4022","PBD","BK4231"],"gpt_icon":0},{"id":"2524220685","title":"ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524220685","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524220685?lang=en_us&edition=fundamental","pubTime":"2025-04-04 14:00","pubTimestamp":1743746400,"startTime":"0","endTime":"0","summary":"Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year. Approval brings Daiichi Sankyo and AstraZeneca’s ENHERTU earlier in the treatment of HR positive, HER2 low breast cancer and broadens the eligible patient population to those with HER2 ultralow disease. HR positive, HER2 negative is the most common breast cancer subtype, accounting for approximately 70% of all breast cancers.1 Despite being classified as HER2 negative, many of these tumors still have some level of HER2 expression. Currently, regardless of HER2 expression, endocrine-based therapies are widely used in the early lines of treatment for HR positive metastatic breast cancer. Following endocrine-based therapy, some patients discontinue treatment, and others are treated with conventional chemotherapy which is associated with poor response rates and outcomes.2,3,4,5. In the DESTINY-Breast06 trial, ENHERT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-approved-eu-first-her2-060000976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HR","DSKYF","BK4007","BK4195","BK4211","BK4225","PBD","ADC","BK4203","BK4231","ORR","BK4080","DSNKY","BK4156","PFS"],"gpt_icon":0},{"id":"2523958946","title":"DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523958946","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523958946?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"TOKYO & BASKING RIDGE, N.J., March 31, 2025----The first patient has been dosed in the DESTINY-Gastric05 phase 3 trial evaluating ENHERTU  in combination with a fluoropyrimidine chemotherapy  and Merck’s  anti-PD-1 therapy KEYTRUDA  versus trastuzumab in combination with platinum-based chemotherapy  and pembrolizumab in previously untreated patients with unresectable, locally advanced or metastatic HER2 positive  gastric or gastroesophageal junction  cancer with PD-L1 CPS ≥1. An exploratory cohort of patients with PD-L1 CPS <1 will be randomized to either ENHERTU plus fluoropyrimidine or trastuzumab plus platinum-based chemotherapy.Gastric cancer is associated with a poor prognosis, particularly in advanced stages of the disease where the five-year survival rate is 5% to 10%.1 Current recommended first-line treatment for HER2 positive advanced gastric cancer with PD-L1 CPS ≥1 is trastuzumab in combination with platinum-based chemotherapy  and pembrolizumab.2,3 New treatment strategies ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/destiny-gastric05-phase-3-trial-120000580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","HR","PBD","BK4231","ADC","BK4211","IE00B19Z4B17.USD","AEIS","BK4225","IE0031619046.USD","BK4007","BK4195","BK4203","BK4157","DSKYF","DSNKY","PFS","IE00B66KJ199.SGD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2522379277","title":"Press Release: ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522379277","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522379277?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:30","pubTimestamp":1743075000,"startTime":"0","endTime":"0","summary":"ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update. Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025. Completed enrollment in LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab in patients with 2L+ DLBCL; data update anticipated in late 2025 once PFS events reached. $250.9M in cash as of December 31, 2024, provides runway expected to fund operations into the second half of 2026. LAUSANNE, Switzerland, March 27, 2025 /PRNewswire/ -- ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates , today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent operational updates.Fourth Quarter 2024 Operational Updates and Upcoming Milestones. and the complete response rate  was 72%. Th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","03160","BK4195","ADC","BK4505","PBD","LENZ","ASH","TM","R","BK4231","BK4099","ADCT","BK4080","BK4588","BK4109","BK4094","BK4139","BK4555","BK4585","BK4232","BK4604","BK4022","PFS","FL","ORR","LU2463526074.USD"],"gpt_icon":0},{"id":"2516920633","title":"ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516920633","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516920633?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"Phase 3 results confirm the efficacy of Daiichi Sankyo and AstraZeneca’s ENHERTU in second-line metastatic gastric cancer. DESTINY-Gastric04 will be unblinded at interim analysis based on the superior efficacy of ENHERTU. TOKYO & BASKING RIDGE, N.J., March 03, 2025----Positive topline results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU  demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of overall survival  compared to ramucirumab and paclitaxel in patients with second-line HER2 positive  unresectable and/or metastatic gastric or gastroesophageal junction  adenocarcinoma.\"We are committed to advancing the care of patients with metastatic gastric cancer and continuing to understand the role of ENHERTU in earlier lines of treatment,\" said Susan Galbraith, MBBChir, PhD, Executive Vice President, Oncology Hematology R&D, AstraZeneca. \"The results of DESTINY-Gastric04 show that second-line treatment with ENHERTU can extend surv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-demonstrated-statistically-significant-clinically-130000294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HR","DSKYF","BK4007","BK4225","BK4097","BK4203","ADC","BK4231","PBD","BK4080","OS","DSNKY"],"gpt_icon":0},{"id":"2514329672","title":"ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514329672","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514329672?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:00","pubTimestamp":1740747600,"startTime":"0","endTime":"0","summary":"Recommendation based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year. TOKYO & MUNICH, February 28, 2025----Daiichi Sankyo  and AstraZeneca’s  ENHERTU  has been recommended for approval in the European Union  as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor  positive, HER2 low  or HER2 ultralow  breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate  discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.In the DESTINY-Breast06 trial, ENHERTU demonstrated a 38% reduction in the risk of disease progression or death versus chemotherapy in patients with chemotherapy-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-recommended-approval-eu-chmp-130000849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBD","BK4203","BK4211","CHMP","BK4156","BK4195","BK4007","BK4231","HR","BK4225","ADC","DSNKY","PFS","BK4080","ORR","DSKYF","BK4087"],"gpt_icon":0},{"id":"2507957937","title":"Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2507957937","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507957937?lang=en_us&edition=fundamental","pubTime":"2025-01-31 21:00","pubTimestamp":1738328400,"startTime":"0","endTime":"0","summary":"Recommendation based on TROPION-Breast01 results showing Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced risk of disease progression or death by 37% versus chemotherapy. Datopotamab deruxtecan approved in the U.S. and Japan for same patient population. TOKYO & MUNICH, January 31, 2025----Datopotamab deruxtecan  has been recommended for approval in the European Union  for the treatment of adult patients with unresectable or metastatic hormone receptor  positive, HER2 negative  breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.Datopotamab deruxtecan demonstrated a favorable safety profile over chemotherapy with no new safety concerns identified. Grade 3 or higher treatment-related adverse events  occurred in 21% and 45% of patients in the datopotamab deruxtecan and chemotherapy arms, respectively. The most common grade 3 or higher TRAEs were neutropenia , stomatitis , fatigue  and anemia . In the datopotamab de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datopotamab-deruxtecan-recommended-approval-eu-130000461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","CHMP","BK4007","BK4156","PFS","DSNKY","BK4195","PBD","ORR","CR","ADC","BK4231","BK4211","DSKYF","BK4225","BK4203","BK4087","BK4213","PR","HR","BK4161"],"gpt_icon":0},{"id":"2507841229","title":"TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse","url":"https://stock-news.laohu8.com/highlight/detail?id=2507841229","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507841229?lang=en_us&edition=fundamental","pubTime":"2025-01-31 12:00","pubTimestamp":1738296000,"startTime":"0","endTime":"0","summary":"TOKYO & BASKING RIDGE, N.J., January 31, 2025----The first patient has been dosed in the TROPION-Lung12 phase 3 trial evaluating the efficacy and safety of adjuvant DATROWAY  plus rilvegostomig or rilvegostomig monotherapy versus standard of care in patients with stage 1 adenocarcinoma non-small cell lung cancer  after complete surgical resection who are ctDNA-positive or have other high risk pathological features.\"With TROPION-Lung12, we are simultaneously deploying a novel strategy for identifying patients with lung cancer who are at an increased risk of disease recurrence after surgery and evaluating novel treatment options in the adjuvant setting, including rilvegostomig with and without DATROWAY,\" said Cristian Massacesi, MD, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca. \"The ambitious approach in this trial underscores our commitment to both enabling more personalized treatment decisions and delivering innovative treatment options to patients with can","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tropion-lung12-phase-3-trial-040000069.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4203","DSNKY","BK4225","HR","BK4007","BK4231","ADC","SSI","DSKYF","BK4080","PBD"],"gpt_icon":0},{"id":"2503582012","title":"Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH","url":"https://stock-news.laohu8.com/highlight/detail?id=2503582012","media":"Business Wire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503582012?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:00","pubTimestamp":1736784000,"startTime":"0","endTime":"0","summary":"TOKYO & BASKING RIDGE, N.J., January 13, 2025----Daiichi Sankyo Company, Ltd  announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated mucin-1  antibody, gatipotuzumab. Such payment by Daiichi Sankyo satisfies all potential clinical, regulatory and sales milestone payments, as well as royalties of products that include gatipotuzumab as part of a 2018 licensing agreement between the parties. In 2018, Daiichi Sankyo in-licensed exclusive rights to develop and commercialize gatipotuzumab worldwide as an antibody drug conjugate  from Glycotope.The anti-TA-MUC1 is the antibody contained in DS-3939, an ADC being developed by Daiichi Sankyo. DS-3939 is a specifically engineered potential first-in-class TA-MUC1 directed medicine designed using Daiichi Sankyo’s proprietary DXd ADC technology. DS-3939 is currently being evaluated in a phase 1/2 clinical trial in patients with several types of advanced solid tumors including no","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/daiichi-sankyo-acquires-intellectual-property-160000039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBD","DSNKY","BK4231","BK4007","DSKYF","BK4080","ADC"],"gpt_icon":0},{"id":"2503326508","title":"Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2503326508","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503326508?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:00","pubTimestamp":1736751600,"startTime":"0","endTime":"0","summary":"Application based on TROPION-Lung05 phase 2 trial and supported by data from TROPION-Lung01 phase 3 and TROPION-PanTumor01 phase 1 trials. TOKYO & BASKING RIDGE, N.J., January 13, 2025----Daiichi Sankyo  and AstraZeneca’s  Biologics License Application  for datopotamab deruxtecan  has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated  non-small cell lung cancer  who have received prior systemic therapies, including an EGFR-directed therapy.Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate  discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca.\"Acquired resistance to front-line therapies and, ultimately, disease progression are unfortunate realities for most patients with advanced EGFR-mutated non-small cell lung cancer,\" said Susan Galbraith, MBBChir, PhD, Executive Vice President, Oncology","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datopotamab-deruxtecan-granted-priority-review-070000802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","PBD","DSKYF","IE0031619046.USD","IE00B7SZL793.SGD","OS","BK4195","ADC","BK4211","IE00B66KJ199.SGD","AEIS","BK4097","IE00B19Z4B17.USD","BK4080","BK4007","PFS","BK4157","DSNKY"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBD\",params:#limit:5,,,undefined,":[{"date":"2025-06-23","symbol":"PBD","amount":0.13639,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Global Clean Energy ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-24","symbol":"PBD","amount":0.09252,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"Invesco Global Clean Energy ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PBD","amount":0.04487,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"Invesco Global Clean Energy ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-27"},{"date":"2024-09-23","symbol":"PBD","amount":0.07114,"announcedDate":"2024-09-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-23","defaultRemindTime":1727098200000,"name":"Invesco Global Clean Energy ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-27","payableDate":"2024-09-23","currency":"USD","dateTimestamp":1727064000000,"payDate":"2024-09-27"},{"date":"2024-06-24","symbol":"PBD","amount":0.08667,"announcedDate":"2024-06-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Global Clean Energy ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBD\",market:\"US\",,,undefined,":[{"executeDate":"2015-09-18","recordDate":"2015-09-22","paymentDate":"2015-09-30","value":0.0237,"currency":"USD"},{"executeDate":"2015-12-18","recordDate":"2015-12-22","paymentDate":"2015-12-31","value":0.07386,"currency":"USD"},{"executeDate":"2016-06-17","recordDate":"2016-06-21","paymentDate":"2016-06-30","value":0.0645,"currency":"USD"},{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-30","value":0.06879,"currency":"USD"},{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-30","value":0.0793,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBD\",market:\"US\",delay:false,,,undefined,":{}}}